ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NA Nano Labs Ltd

8.42
0.15 (1.81%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nano Labs Ltd NASDAQ:NA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 1.81% 8.42 8.01 8.99 9.00 7.87 7.87 10,450 22:00:00

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

21/11/2024 9:00pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2024

 

Commission File Number: 001-41426

 

Nano Labs Ltd

(Exact name of registrant as specified in its charter)

 

China Yuangu Hanggang Technology Building

509 Qianjiang Road, Shangcheng District,

Hangzhou, Zhejiang, 310000

People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

 

Interim Condensed Balance Sheet as of September 30, 2024

 

Nano Labs Ltd (the “Company”) sets forth the preliminary unaudited condensed balance sheet as of September 30, 2024, which have been prepared by, and are the responsibility of, the Company’s management. The preliminary financial data are based on the information currently available to us as of the date of this report.

 

Nano Labs Ltd

Consolidated Balance Sheets

(Unaudited)

 

   As of
Sept 30,
   As of
Sept 30,
 
   2024   2024 
   RMB   US$* 
         
ASSETS        
Current assets:        
Cash and cash equivalents   50,322,415    7,181,325 
Restricted cash   418,201    59,680 
Accounts receivable, net   2,178,747    310,921 
Inventories, net   10,191,230    1,454,353 
Prepayments   24,155,244    3,447,105 
Other current assets   52,524,971    7,495,643 
Total current assets   139,790,808    19,949,026 
Non-current assets:          
Property, plant and equipment, net   197,476,913    28,181,196 
Intangible asset, net   46,991,905    6,706,040 
Operating lease right-of-use assets   7,028,136    1,002,959 
Total non-current assets   251,496,954    35,890,195 
TOTAL ASSETS   391,287,762    55,839,222 
           
LIABILITIES AND SHAREHOLDERS' EQUITY          
Current liabilities:          
Short-term debts   20,000,000    2,854,126 
Current portion of long-term debts   4,580,000    653,595 
Accounts payable   12,481,588    1,781,201 
Advance from customers   83,505,919    11,916,819 
Operating lease liabilities, current   2,877,067    410,576 
Other current liabilities   70,839,217    10,109,201 
Total current liabilities   194,283,792    27,725,518 
Non-current liabilities:          
Long-term debts   169,833,636    24,236,327 
Operating lease liabilities, non-current   3,938,711    562,079 
Total non-current liabilities   173,772,347    24,798,406 
Total liabilities   368,056,139    52,523,923 
Shareholders' equity :          
Class A ordinary shares   100,584    14,354 
Class B ordinary shares   36,894    5,265 
Additional paid-in capital   531,220,288    75,808,472 
Accumulated deficit   (519,783,722)   (74,176,402)
Statutory reserves   6,647,109    948,584 
Accumulated other comprehensive income   5,010,470    715,026 
Total Nano Labs Ltd shareholders' equity   18,516,603    2,642,436 
Noncontrolling interests   4,715,020    672,863 
Total shareholders' equity   23,231,623    3,315,299 
           
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY   391,287,762    55,839,222 

 

*Convenient translation rate is US$1 = RMB7.0074

 

1

 

 

In accordance with Nasdaq Listing Rule 5550(b)(1), the Company is required to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on The Nasdaq Capital Market. Based on the financial statements for the six months ended/as of June 30, 2024, as disclosed by the Company on September 18, 2024, the Company had fallen below this requirement.

 

During the three months ended September 30, 2024, the Company entered into agreements with Mr. Jianping Kong, its chairman and chief executive officer, and Mr. Qifeng Sun, its vice chairman, along with their respective affiliates (the “Lenders”) on September 20, 2024, to convert the interest-free loans from the Lenders in an aggregated amount of US$8.5 million into certain amount of Class A ordinary shares (the “Conversion”) in lieu of repayment of the Loans. The Conversion has been closed on September 23, 2024. This transaction has strengthened the Company’s financial position and increased its stockholders’ equity. As of the date the Company furnished this report, the Company reasonably believes it is compliant with Nasdaq Capital Market’s minimum stockholders' equity requirement of $2.5 million as a result of the aforementioned transaction.

 

The Company acknowledges that Nasdaq will continue to monitor its ongoing compliance with the stockholders’ equity requirement. If at the time of its next periodic report the Company does not evidence compliance with this requirement, it may be subject to delisting from The Nasdaq Capital Market.

 

This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3, as amended, initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2023 (Registration No. 333-273968) and a prospectus supplement dated April 11, 2024 thereunder, and shall be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Forward-Looking Statements

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s compliance with the relevant Nasdaq continued listing standards, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s compliance status, actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Nano Labs Ltd
     
Date: November 21, 2024 By: /s/ Jianping Kong
  Name:  Jianping Kong
  Title: Chairman and Chief Executive Officer

 

 

3

 

 


1 Year Nano Labs Chart

1 Year Nano Labs Chart

1 Month Nano Labs Chart

1 Month Nano Labs Chart

Your Recent History

Delayed Upgrade Clock